Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ALBIREO PHARMA, INC. | Chief Medical Officer | Common Stock | 12.4K | $541K | $43.80 | Oct 22, 2021 | Direct |
Fulcrum Therapeutics, Inc. | Chief Medical Officer | Stock Option (right to buy) | 400K | Mar 18, 2024 | Direct | ||
Fulcrum Therapeutics, Inc. | Chief Medical Officer | No securities are beneficially owned | 0 | Mar 18, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
FULC | Fulcrum Therapeutics, Inc. | Mar 18, 2024 | 1 | $0 | 4 | Mar 20, 2024 | Chief Medical Officer |
FULC | Fulcrum Therapeutics, Inc. | Mar 18, 2024 | 0 | $0 | 3 | Mar 20, 2024 | Chief Medical Officer |
ALBO | ALBIREO PHARMA, INC. | Oct 22, 2021 | 1 | -$2.74K | 4 | Oct 25, 2021 | Chief Medical Officer |
ALBO | ALBIREO PHARMA, INC. | Jul 22, 2021 | 1 | -$3.07K | 4 | Jul 26, 2021 | Chief Medical Officer |